Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial

OBJECTIVES: To report the safety and immunogenicity profile of a protein subunit vaccine (MVC-COV1901) compared to AZD1222 and mRNA-1273 when given as a third (booster) dose to individuals who have completed different primary vaccine regimens. METHODS: Individuals were classified according to their...

Descripción completa

Detalles Bibliográficos
Autores principales: Estephan, Lila, Lin, Ying-Chin, Lin, Yi-Tsung, Chen, Yen-Hsu, Pan, Sung-Ching, Hsieh, Szu-Min, Torkehagen, Paal Fure, Weng, Yi-Jen, Cheng, Hao-Yuan, Estrada, Josue Antonio, Waits, Alexander, Chen, Charles, Lien, Chia En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090360/
https://www.ncbi.nlm.nih.gov/pubmed/37080829
http://dx.doi.org/10.1016/j.vaccine.2023.04.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090360/
https://www.ncbi.nlm.nih.gov/pubmed/37080829
http://dx.doi.org/10.1016/j.vaccine.2023.04.029

Ejemplares similares